BankPlus Wealth Management LLC Purchases Shares of 1,970 Danaher Co. (NYSE:DHR)

BankPlus Wealth Management LLC purchased a new stake in Danaher Co. (NYSE:DHR) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,970 shares of the conglomerate’s stock, valued at approximately $452,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Coronation Fund Managers Ltd. lifted its position in shares of Danaher by 29.9% during the 2nd quarter. Coronation Fund Managers Ltd. now owns 6,389 shares of the conglomerate’s stock worth $1,596,000 after buying an additional 1,470 shares in the last quarter. Ascent Group LLC raised its stake in shares of Danaher by 30.2% during the second quarter. Ascent Group LLC now owns 2,205 shares of the conglomerate’s stock worth $551,000 after acquiring an additional 512 shares in the last quarter. Creative Planning grew its holdings in shares of Danaher by 6.0% in the second quarter. Creative Planning now owns 122,591 shares of the conglomerate’s stock worth $30,629,000 after purchasing an additional 6,969 shares during the last quarter. NewEdge Advisors LLC increased its stake in shares of Danaher by 36.9% during the second quarter. NewEdge Advisors LLC now owns 49,460 shares of the conglomerate’s stock valued at $12,357,000 after buying an additional 13,338 shares during the period. Finally, Quarry LP raised its holdings in shares of Danaher by 250.6% during the second quarter. Quarry LP now owns 298 shares of the conglomerate’s stock valued at $74,000 after acquiring an additional 213 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on DHR shares. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Royal Bank of Canada reduced their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. UBS Group lowered their price objective on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Scotiabank began coverage on Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price for the company. Finally, Raymond James dropped their price target on Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 21st. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Stock Up 1.9 %

DHR stock opened at $250.51 on Tuesday. Danaher Co. has a 1-year low of $225.42 and a 1-year high of $281.70. The business has a fifty day moving average price of $235.33 and a 200-day moving average price of $253.62. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The stock has a market capitalization of $180.94 billion, a P/E ratio of 47.81, a P/E/G ratio of 4.43 and a beta of 0.83.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s dividend payout ratio is presently 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.